# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jesse Owens (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML042-SYN
- Date: 2026-05-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Clarence Whitfield-Arroyo, MD
- Calendar frame: modern shifted

## Subjective

The patient participates in this fictional visit for new patient visit: shared decision-making for lung cancer screening, same-day low-dose CT showing a suspicious left upper lobe nodule, and tobacco treatment. **S**

## Objective

Hemoglobin: 15.1 g/dL; White cell count: 8.4 10*3/uL; Platelets: 262 10*3/uL; Sodium: 139 mmol/L; Potassium: 4.2 mmol/L; Creatinine: 1 mg/dL; eGFR (CKD-EPI 2021): 84 mL/min/1.73 m²; Glucose: 94 mg/dL; Calcium: 9.4 mg/dL; Albumin: 4.2 g/dL; ALT: 22 U/L; AST: 21 U/L; Alkaline phosphatase: 84 U/L; Total bilirubin: 0.6 mg/dL; PHQ-2: 1. All results are synthetic.

BP 134/82 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 95% on room air; weight 77 kg; BMI 24.3 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Solid, spiculated 2.9 cm nodule in the left upper lobe with an enlarged (1.6 cm) left hilar lymph node on today's low-dose screening CT, Lung-RADS 4X (very suspicious); no symptoms of lung cancer. PET-CT, tissue diagnosis and thoracic oncology review booked; Nicotine dependence, cigarettes: a pack a day for 35 years (35 pack-years); smokes his first cigarette within 30 minutes of waking; two attempts to stop, each lasting a few weeks without medicine. Strengths and supports remain part of the care plan. **S**

## Medication changes

- No medication changes. **S**

## Plan

- Referral to thoracic oncology: consultation within two weeks to review the screening CT, PET-CT and EBUS results with him and plan treatment. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026) **S**
- Work-up of the Lung-RADS 4X nodule without delay: FDG PET-CT and brain MRI with contrast this week, then endobronchial ultrasound with systematic sampling of mediastinal and hilar nodes (at least stations 4R, 4L and 7, and any PET-avid node), with enough tissue for PD-L1 and comprehensive next-generation sequencing (EGFR, ALK, ROS1, BRAF, KRAS, MET exon 14, RET, NTRK, HER2) and plasma testing in parallel; nurse navigator to track each date. Guideline: NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); US Preventive Services Task Force. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2021;325(10):962-970 (PMID 33687470) (2021); Mazzone PJ, et al. Screening for Lung Cancer: CHEST Guideline and Expert Panel Report. Chest 2021;160(5):e427-e494 (PMID 34270968) (2021); Lung CT Screening Reporting and Data System (Lung-RADS) v2022 (2022); Silvestri GA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: ACCP evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e211S-e250S (PMID 23649440) (2013) **S**
- Tobacco treatment at every visit: brief advice, varenicline offered with a quit date, the Arizona quitline and counseling; stopping smoking improves outcomes even after a lung cancer diagnosis. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021) **S**
- Equity safeguards: a nurse navigator, written results and next steps at each visit, transport and cost help offered, and time from scan to treatment tracked against the goal. Guideline: Aldrich MC, et al. Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers. JAMA Oncol 2019;5(9):1318-1324 (PMID 31246249) (2019); Bach PB, et al. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 1999;341(16):1198-1205 (PMID 10519898) (1999) **S**
- Distress and depression screening at each visit, plain information he can share, and advance care planning when he is ready. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026) **S**
